Literature DB >> 19701707

GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients.

Aurora Arrúe1, Ricardo Dávila, Mercedes Zumárraga, Nieves Basterreche, Miguel A González-Torres, Biotza Goienetxea, Maria I Zamalloa, Juan B Anguiano, José Guimón.   

Abstract

We have determined the plasma (p) concentration of gamma-aminobutyric acid (GABA) and the dopamine metabolite homovanillic acid (HVA), and the pHVA/pGABA ratio in schizophrenic and bipolar patients. The research was undertaken in a geographic area with an ethnically homogeneous population. The HVA plasma concentrations were significantly elevated in the schizophrenic patients compared to the bipolar patients. The levels of pGABA was significantly lower in the two groups of patients compared to the control group, while the pHVA/pGABA ratio was significantly greater in the both groups of patients compared to the controls. As the levels of pHVA and pGABA are partially under genetic control it is better to compare their concentrations within an homogeneous population. The values of the ratio pHVA/pGABA are compatible with the idea of an abnormal dopamine-GABA interaction in schizophrenic and bipolar patients. The pHVA/pGABA ratio may be a good peripheral marker in psychiatric research.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19701707     DOI: 10.1007/s11064-009-0048-z

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  50 in total

1.  Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients.

Authors:  M Toru; S Watanabe; H Shibuya; T Nishikawa; K Noda; H Mitsushio; H Ichikawa; A Kurumaji; M Takashima; N Mataga
Journal:  Acta Psychiatr Scand       Date:  1988-08       Impact factor: 6.392

Review 2.  Measurement of plasma homovanillic acid concentrations in schizophrenic patients.

Authors:  R Kaminski; P Powchick; P A Warne; M Goldstein; R T McQueeney; M Davidson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1990       Impact factor: 5.067

3.  Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

Authors:  Shingo Kakihara; Reiji Yoshimura; Koji Shinkai; Chima Matsumoto; Makiko Goto; Kyoko Kaji; Yasuhisa Yamada; Nobuhisa Ueda; Osamu Ohmori; Jun Nakamura
Journal:  Int Clin Psychopharmacol       Date:  2005-03       Impact factor: 1.659

4.  Evidence for the segregation of a major gene for human plasma GABA levels.

Authors:  F Petty; M Fulton; G L Kramer; M Kram; L L Davis; A J Rush
Journal:  Mol Psychiatry       Date:  1999-11       Impact factor: 15.992

Review 5.  GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon.

Authors:  Alessandro Guidotti; James Auta; John M Davis; Erbo Dong; Dennis R Grayson; Marin Veldic; Xianquan Zhang; Erminio Costa
Journal:  Psychopharmacology (Berl)       Date:  2005-04-28       Impact factor: 4.530

6.  The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients.

Authors:  P E Konicki; R R Owen; R E Litman; D Pickar
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

7.  Pretreatment plasma HVA and haloperidol response in acute mania.

Authors:  J C Chou; P Czobor; I Tuma; O Charles; R Bebe; T B Cooper; W H Chang; H Y Lane; D L Stone
Journal:  J Affect Disord       Date:  2000-07       Impact factor: 4.839

8.  Plasma GABA levels in psychiatric illness.

Authors:  F Petty; A D Sherman
Journal:  J Affect Disord       Date:  1984-04       Impact factor: 4.839

9.  Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients.

Authors:  M Davidson; M F Losonczy; R C Mohs; J C Lesser; P Powchik; L B Freed; B M Davis; V V Mykytyn; K L Davis
Journal:  Neuropsychopharmacology       Date:  1987-12       Impact factor: 7.853

10.  Plasma catecholamine metabolites in antidepressant-exacerbated mania and psychosis.

Authors:  Frank Fortunati; Carolyn Mazure; Adrian Preda; Rebecca Wahl; Malcolm Bowers
Journal:  J Affect Disord       Date:  2002-04       Impact factor: 4.839

View more
  10 in total

Review 1.  Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.

Authors:  Chi-Yu Lai; Elizabeth Scarr; Madhara Udawela; Ian Everall; Wei J Chen; Brian Dean
Journal:  World J Psychiatry       Date:  2016-03-22

2.  Guanidinoacetic acid loading affects plasma γ-aminobutyric acid in healthy men.

Authors:  Sergej M Ostojic; Marko Stojanovic
Journal:  Eur J Nutr       Date:  2015-02-14       Impact factor: 5.614

3.  Variability of plasma homovanillic acid over 13 months in patients with schizophrenia; relationship with the clinical response and the Wisconsin card sort test.

Authors:  Mercedes Zumárraga; Miguel A González-Torres; Aurora Arrue; Ricardo Dávila; Wendy Dávila; Lucía Inchausti; Lucía Pérez-Cabeza; Aránzazu Fernández-Rivas; Sonia Bustamante; Nieves Basterreche; José Guimón
Journal:  Neurochem Res       Date:  2011-04-08       Impact factor: 3.996

Review 4.  Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.

Authors:  Masataka Wada; Yoshihiro Noda; Yusuke Iwata; Sakiko Tsugawa; Kazunari Yoshida; Hideaki Tani; Yoji Hirano; Shinsuke Koike; Daiki Sasabayashi; Haruyuki Katayama; Eric Plitman; Kazutaka Ohi; Fumihiko Ueno; Fernando Caravaggio; Teruki Koizumi; Philip Gerretsen; Takefumi Suzuki; Hiroyuki Uchida; Daniel J Müller; Masaru Mimura; Gary Remington; Anthony A Grace; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2022-04-20       Impact factor: 15.992

5.  Serial plasma metabolites following hypoxic-ischemic encephalopathy in a nonhuman primate model.

Authors:  Pattaraporn T Chun; Ronald J McPherson; Luke C Marney; Sahar Z Zangeneh; Brendon A Parsons; Ali Shojaie; Robert E Synovec; Sandra E Juul
Journal:  Dev Neurosci       Date:  2015-02-27       Impact factor: 2.984

6.  Characterization of choline transporters in the human placenta over gestation.

Authors:  Heidi K Baumgartner; Kinsey M Trinder; Carly E Galimanis; Annalisa Post; Tzu Phang; Randal G Ross; Virginia D Winn
Journal:  Placenta       Date:  2015-10-09       Impact factor: 3.481

7.  γ-Aminobutyric acid transporter 2 mediates the hepatic uptake of guanidinoacetate, the creatine biosynthetic precursor, in rats.

Authors:  Masanori Tachikawa; Saori Ikeda; Jun Fujinawa; Shirou Hirose; Shin-ichi Akanuma; Ken-ichi Hosoya
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

Review 8.  Theranostic Biomarkers for Schizophrenia.

Authors:  Matea Nikolac Perkovic; Gordana Nedic Erjavec; Dubravka Svob Strac; Suzana Uzun; Oliver Kozumplik; Nela Pivac
Journal:  Int J Mol Sci       Date:  2017-03-30       Impact factor: 5.923

9.  Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion.

Authors:  Tanja Veselinović; Ingo Vernaleken; Paul Cumming; Uwe Henning; Lina Winkler; Peter Kaleta; Michael Paulzen; Christian Luckhaus; Gerhard Gründer
Journal:  Neuropsychiatr Dis Treat       Date:  2018-04-27       Impact factor: 2.570

10.  Plasma amino acids profile in first-episode psychosis, unaffected siblings and community-based controls.

Authors:  Camila Marcelino Loureiro; Daiane Leite da Roza; Fabiana Corsi-Zuelli; Rosana Shuhama; Helene Aparecida Fachim; Lívia Maria Cordeiro Simões-Ambrosio; Rafael Deminice; Alceu Afonso Jordão; Paulo Rossi Menezes; Cristina Marta Del-Ben; Paulo Louzada-Junior
Journal:  Sci Rep       Date:  2020-12-08       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.